Processes for preparing oxathiazin-like compounds
Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
1 . A method of reducing or inhibiting cancer cell migration in a subject in need thereof comprising administering 0.1 g to about 100 g of a compound of formula I
wherein R is H, an alkyl, or benzyl, to the subject, wherein the compound is administered orally, intravenously, topically, or a combination thereof.
2 . The method of claim 1 , wherein the compound is administered orally, intravenously, or a combination thereof.
3 . The method of claim 1 , wherein the compound is
4 . The method of claim 1 , wherein the subject has a pancreatic cancer, an ovarian cancer, a mesothelioma, a melanoma, or a squamous cell carcinoma.
5 . The method of claim 1 , comprising administering 5 g to about 30 g of the compound per day.
6 . The method of claim 1 , comprising administering the compound in a gel, capsule, tablet, or solution.
7 . The method of claim 1 , comprising administering the compound in a pharmaceutical composition at a concentration of about 0.01 to about 3% w/v.
8 . The method of claim 1 , comprising administering the compound in a pharmaceutical composition at a concentration of about 0.01 μg/ml to about 1000 μg/ml.
9 . The method of claim 1 , comprising administering the compound in a pharmaceutical composition containing about 0.01 to about 3% taurolidine and/or taurultam.
10 . The method of claim 1 , wherein the subject has a tumor, cancerous cells, pre-cancerous cells, or cancer stem cells, is suspected of having a tumor, cancerous cells, pre-cancerous cells, or cancer stem cells, or is at risk of developing a tumor, cancerous cells, pre-cancerous cells, cancer stem cells or metastases thereof.
11 . A method of treating a subject having a squamous cell carcinoma, an ovarian cancer, or a pancreatic cancer comprising administering an effective amount of a compound, wherein the compound is
to the subject, wherein the compound is administered orally, intravenously, topically, or a combination thereof.
12 . The method of claim 11 , wherein the squamous cell carcinoma is a cutaneous squamous cell carcinoma.
13 . The method of claim 11 , wherein the compound is administered orally, intravenously, or a combination thereof.
14 . The method of claim 11 , comprising administering 0.1 g to about 100 g of the compound per day.
15 . The method of claim 11 , comprising administering 5 g to about 30 g of the compound per day.
16 . The method of claim 11 , comprising administering the compound in a gel, capsule, tablet, or solution.
17 . The method of claim 11 , comprising administering the compound in a pharmaceutical composition at a concentration of about 0.01 to about 3% w/v.
18 . The method of claim 11 , comprising administering the compound in a pharmaceutical composition at a concentration of about 0.01 μg/ml to about 1000 μg/ml.
19 . The method of claim 11 , comprising administering the compound in a pharmaceutical composition containing about 0.01 to about 3% taurolidine and/or taurultam.